Adult and paediatric poor metabolisers of desloratadine: An assessment of pharmacokinetics and safety

Expert Opinion on Drug Safety

Volumn 5, Issue 2, 2006, Pages 211-223

  Prenner, Bruce ^a   Kim, Kenneth ^b   Gupta, Samir ^c   Khalilieh, Sauzanne ^c   Kantesaria, Bhavna ^c   Manitpisitkul, Prasarn ^c   Lorber, Richard ^c   Wang, Zaiqi ^c   Lutsky, Barry ^c  

^a Allergy Associates Medical Group Inc   (United States)

^b West Coast Clinical Trials LLC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Allergic rhinitis (AR); Antihistamine; Chronic idiopathic urticaria (CIU); Desloratadine; Electrocardiogram (ECG); Pharmacokinetics; Poor metaboliser

Indexed keywords

3 HYDROXYDESLORATADINE; ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZITHROMYCIN; CETIRIZINE; CHLORPHENIRAMINE; CIMETIDINE; CORTICOSTEROID DERIVATIVE; CYTOCHROME P450 3A4; DESLORATADINE; DIPHENHYDRAMINE; DRUG METABOLITE; ERYTHROMYCIN; FEXOFENADINE; FLUOXETINE; KETOCONAZOLE; LORATADINE; PLACEBO; TERFENADINE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST;

ADULT; AGED; ALLERGIC RHINITIS; AREA UNDER THE CURVE; ATOPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHILD; CHRONIC URTICARIA; CLINICAL TRIAL; COGNITIVE DEFECT; COUGHING; DIARRHEA; DISEASE EXACERBATION; DROWSINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG EXPOSURE; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSMENORRHEA; FATIGUE; FEVER; GENETIC POLYMORPHISM; HEADACHE; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; MYALGIA; PHARYNGITIS; PHENOTYPE; PREVALENCE; PSYCHOMOTOR DISORDER; QT PROLONGATION; REVIEW; SOMNOLENCE; TORSADE DES POINTES; VIRUS INFECTION; XEROSTOMIA; AGE; DOSE RESPONSE; ELECTROCARDIOGRAPHY; HAY FEVER; METABOLISM; ORAL DRUG ADMINISTRATION; URTICARIA;

ADMINISTRATION, ORAL; AGE FACTORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; LORATADINE; RHINITIS, ALLERGIC, SEASONAL; URTICARIA;

EID: 33644906907     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.2.211     Document Type: Review

References (70)

1. BACHERT C, VAN CAUWENBERGE P, KHALTAEV N with the World Health Organization: Allergic rhinitis and its impact on asthma. In collaboration with the World Health Organization. Executive Summary of the Workshop Report. 7-10 December 1999, Geneva, Switzerland. Allergy (2002) 57(9):841-855.
2. SKONER DP: Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J. Allergy Clin. Immunol. (2001) 108(Suppl. 1):2-8.
3. MULLER BA: Urticaria and angioedema: a practical approach. Am. Fam. Physician (2004) 69(5):1123-1128.
4. GREAVES MW- Chronic idiopathic urticaria. Curr. Opin. Allergy Clin. Immunol. (2003) 3(5):363-368.
5. BOUSQUET J, BULLINGER M, FAYOL C, MARQUIS P, VALENTIN B, BURTIN B: Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J. Allergy Clin. Immunol. (1994) 94(2):182-188.
6. LEYNAERT B, NEUKIRCH C, LIARD R, BOUSQUET J, NEUKIRCH F: Quality of life in allergic rhinitis and asthma. A opulation-based study of young adults. Am. J. Respir. Crit. Care Med. (2000) 162(4):1391-1396.
7. EUROPEAN ACADEMY OF ALLERGOLOLGY AND CLINICAL IMMUNOLOGY: The impact of allergic rhinitis on quality of life and other airway diseases. Summary of a European conference. Allergy (1998) 53(Suppl. 41):1-31.
8. JUNIPER EF: Quality of life in adults and children with asthma and rhinitis. Allergy (1997) 52(10):971-977.
9. MELTZER EO: Quality of life in adults and children with allergic rhinitis. J. Allergy Clin. Immunol. (2001) 108(Suppl. 1):45-53.
10. O'DONNELL BF, LAWLOR F, SIMPSON J et al.: The impact of chronic urticaria on the quality of life. Br. J. Dermatol. (1997) 136(2):197-201.
11. KOZEL MM, SABROE RA: Chronic urticaria. Aetiology, management and current and future treatment options. Drugs (2004) 64(22):2515-2536.
12. RING J, BROCKOW K, OLLERT M, ENGST R: Antihistamines in urticaria. Clin. Exp. Allergy (1999) 29(Suppl. 1):31-37.
13. GRATTAN C, POWELL S, HUMPHREYS F: Management and diagnostic guidelines for urticaria and angio-oedema. Br. J. Dermatol. (2001) 144(4):708-714.
14. AGRAWAL DK: Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opin. Investig. Drugs (2001) 10(3):547-560.
15. GEHA RS, MELTZER EO: Desloratadine: a new, nonsedating, oral antihistamine. J. Allergy Clin. Immunol. (2001) 107(4):751-762.
16. ANTHES JC, GILCHREST H, RICHARD C et al.: Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur. J. Pharmacol. (2002) 449(3):229-237.
17. VUURMAN EF, RIKKEN CH, MUNTJEWERFF ND, DE HALLEUX F, RAMAEKERS JG: Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur. J. Clin. Pharmacol. (2004) 60(5):307-313.
18. BERGER WE: The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf. (2005) 28(12):1101-1118.
19. SALMUN LM, LORBER R: 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. BMC Fam. Pract. (2002) 3(1):14-19.
20. MELTZER EO, PRENNER BM, NAYAK AS, GROUP DS: Efficacy and tolerability of once-daily 5 mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy season. Clin. Drug Invest. (2001) 21:25-32.
21. NAYAK AS, SCHENKEL E: Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy (2001) 56(11):1077-1080.
22. SIMONS FE, PRENNER BM, FINN A Jr.: Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J. Allergy Clin. Immunol. (2003) 111(3):617-622.
23. BOUSQUET J, BINDSLEV-JENSEN C, CANONICA GW et al.: The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy (2004) 59(Suppl. 77):4-16.
24. MONROE E, FINN A, PATEL P, GUERRERO R, RATNER P, BERNSTEIN D: Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J. Am. Acad. Dermatol. (2003) 48(4):535-541.
25. RING J, HEIN R, GAUGER A, BRONSKY E, MILLER B: Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int. J. Dermatol. (2001) 40(1):72-76.
26. BACHERT C, VIRCHOW CJ, PLENKER A: Desloratadine in the treatment of seasonal allergic rhinitis. Results of a large observational study. Clin. Drug Invest. (2002) 22:43-52.
27. BLOOM M, STAUDINGER H, HERRON J: Safety of desloratadine syrup in children. Curr. Med. Res. Opin. (2004) 20(12):1959-1965.
28. LUTSKY B, LORBER R, BLOOM M: Safety of desloratadine syrup in children 6 months to < 24 months of age: a randomized placebo-controlled study. American College of Allergy, Asthma & Immunology, New Orleans, USA (2003).
29. CASALE TB, BLAISS MS, GELFAND E et al.: First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J. Allergy Clin. Immunol. (2003) 111(5):S835-842.
30. MURDOCH D, GOA KL, KEAM SJ: Desloratadine: an update of its efficacy in the management of allergic disorders. Drugs (2003) 63(19):2051-2077.
31. LIMON L, KOCKLER DR: Desloratadine: a nonsedating antihistamine. Ann. Pharmacother. (2003) 37(2):237-246.
32. WILKEN JA, BERKOWITZ R, KANE R: Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. Ann. Allergy Asthma Immunol. (2002) 89(4):372-380.
33. VALK PJ, VAN ROON DB, SIMONS RM, RIKKEN C: Desloratadine shows no effect on performance during 6 h at 8,000 ft simulated cabin altitude. Aviat. Space Environ. Med. (2004) 75(5):433-438.
34. DUBUSKE LM: Second-generation antihistamines: the risk of ventricular arrhythmias. Clin. Ther. (1999) 21(2):281-295.
35. AFFRIME MB, LORBER R, DANZIG M, CUSS F, BRANNAN MD: Three month evaluation of electrocardiographic effects of loratadine in humans. J. Allergy Clin. Immunol. (1993) 91:Abstract 473.
36. GUPTA S, BANFIELD C, KANTESARIA B et al.: Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin. Ther. (2001) 23(3):451-466.
37. GUPTA S, BANFIELD C: Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. J. Clin. Pharmacol. (2004) 44(11):1252-1259.
38. MOLIMARD M, DIQUET B, BENEDETTI MS: Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam. Clin. Pharmacol. (2004) 18(4):399-411.
39. NORMAN P, DIHLMANN A, RABASSEDA X: Desloratadine: a preclinical and clinical overview. Drugs Today (Barc.) (2001) 37(4):215-227.
40. GHOSAL A, YUAN Y, HAPANGAMA N et al.: Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3-hydroxydesloratadine. Biopharm. Drug Dispos. (2004) 25(6):243-252.
41. MURDOCH D, GOA KL, KEAM SJ: Desloratadine. An update of its efficacy in the management of allergic disorders. Drugs (2003) 63(19):2051-2077.
42. BARECKI ME, CASCIANO CN, JOHNSON WW, CLEMENT RP: In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-deslofatadine for five human cytochrome P450 enzymes. Drug Metab. Dispos. (2001) 29(9):1173-1175.
43. BANFIELD C, HUNT T, REYDERMANN L, STATKEVICH P, PADHI D, AFFRIME M: Lack of clinically relevant interaction between desloratadine and erythromycin. Clin. Pharmacokinet. (2002) 41(Suppl. 1):29-35.
44. BANFIELD C, HERRON J, KEUNG A, PADHI D, AFFRIME M: Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin. Pharmacokinet. (2002) 41 (Suppl. 1):37-44.
45. KHALILIEH S, KRISHNA G, MARINO M et al.: Lack of interaction with coadministration of desloratadine and cimetidine. Ann. Allergy Astbma Immunol. (2002) 88:110.
46. AFFRIME M, GUPTA S, BANFIELD C, COHEN A: A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin. Pharmacokinet. (2002) 41(Suppl. 1):13-19.
47. MEYER U: Pharmacogenetics and adverse drug reactions. Lancet (2000) 356(9242):1667-1671.
48. KHALILIEH S, LUTSKY B, LORBER R: Safety of desloratadine in poor metabolisers. American College of Allergy, Asthma & Immunology, Boston, USA (2004). Poster P248.
49. GUPTA S, KANTESARIA B, WANG Z, KHALILIEH S: Pharmacokinetics of desloratadine in poor metabolizers. American College of Allergy, Asthma & Immunologv, Boston, USA (2004). Poster P249.
50. QIDWAI JC, WATSON GS, WEILER JM: Sedation, cognition, and antihistamines. Curr. Allergy Asthma Rep. (2002) 2(3):216-222.
51. WOOSLEY RL: Cardiac actions of antihistamines. Ann. Rev. Pharmacol. Toxicol. (1996) 36:233-252.
52. HOLLISTER LE: Hydroxyzine hydrochloride: possible adverse cardiac interactions. Psychopharmacol. Commun. (1975) 1(1):61-65.
53. SALATA JJ, JURKIEWICA NZ, WALLACE AA, STUPIENSKI III RF, GUINOSSO PJ, LYNCH JJ: Cardiac electrophysiological actions of H1-receptor antagonists astemizole and terfenadine compared with chlorphenitamine and pyrilamine. Circ. Res. (1995) 76(1):110-119.
54. MANN RD, PEARCE GL, DUNN N, SHAKIR S: Sedation with 'non-sedating' antihistamines: four prescription-event monitoring studies in general practice. Br. Med. J. (2000) 320 (7243):1184-1187.
55. 1 receptor antagonists. Expert Opin. Drug Saf. (2002) 1(3):225-235.
56. GOLIGHTLY LK, GREOS LS: Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs (2005) 65(3):341-384.
57. WILKEN JA, BERKOWITZ R, KANE R: Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. Ann. Allergy Asthma Immunol. (2002) 89(4):372-380.
58. COHEN JP, PAQUETTE C, CAIRNS CP: Switching prescription drugs to over the counter. Br. Med. J. (2005) 330(7481):39-41.
59. YAP YG, CAMM AJ: Potential cardiac toxicity of H1-antihistamines. Clin. Allergy Immunol. (2002) 17:389-419.
60. PAAKKARI I: Cardiotoxicity of new antihistamines and cisapride. Toxicol. Lett. (2002) 127(1-3):279-284.
61. ROY M, DUMAINE R, BROWN AM: HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation (1996) 94(4):817-823.
62. SUESSBRICH H, WALDEGGER S, LANG F, BUSCH AE: Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett. (1996) 385(1-2):77-80.
63. OHMURA T, CHACIN M, TARUI S et al.: Effects of terfenadine, astemizole and epinastine on electrocardiogram in concscious cynomolgus monkeys. Eur. J. Pharmacol. (1999) 378(2):169-175.
64. ZHOU Z, VORPERIAN VR, GONG Q, ZHANG S, JANUARY CT: Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J. Cardiovasc. Electrophysiol. (1999) 10(6):836-843.
65. TAGLIALATELA M, PANNACCIONE A, CASTALDO G et al.: Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol. Pharmacol. (1998) 54(1):113-121.
66. LINDQUIST M, EDWARDS IR: Risks of non-sedating antihistamines. Lancet (1997) 349(9061):1322.
67. GELFAND EW. Pediatric allergic rhinitis; factors affecting treatment choice. Ear Nose Throat J. (2005) 84(3):163-168.
68. HENZ BM: The pharmacologic profile of desloratadine: a review. Allergy (2001) 56(Suppl. 65):7-13.
69. MARINO M, GLUE P, HERRON JM, STATKEVICH P, AFFRIME MB, LIM J: Lack of electrocardiographic effects of multiple high doses of desloratadine. Allergy (2000) 55(Suppl. 63):279.
70. BLUM R, KRAFT W, STEWART JA, MEEVES S, GEORGES G, KOVACS SJ: Short-term safety, tolerability, and pharmacokinetics of desloratadine and fexofenadine in healthy adults identified as desloratadine slow metabolisers (DSMs). J. Allergy Clin. Immunol. (2005) 115(2):S127.